J INTS BIO, Novel Oral 4th Generation EGFR TKI ‘JIN-A02’ – Dosing of First Patient in the Global Multi-center Phase 1/2 Clinical Study began

SEOUL, South Korea, July 31, 2023 /PRNewswire/ — J INTS BIO announced the successful dosing of the first patient in its global multi-center Phase 1/2 clinical study of ‘JIN-A02’ on 31st July at Severance Hospital, Seoul, Korea. More clinical sites will follow suit, including seven more…